Title:
COMPOSITION FOR PREVENTING OR TREATING TNF-α-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENT
Document Type and Number:
WIPO Patent Application WO/2022/098157
Kind Code:
A1
Abstract:
The present invention relates to a composition for preventing or treating a TNF-α-related disease, comprising hydroflumethiazide or a pharmaceutically acceptable salt thereof as an active ingredient, and the present invention can effectively inhibit the expression or activity of TNF-α and exhibits an excellent treatment effect compared to methotrexate (MTX) or hydroxychloroquine (HCQ), which are rheumatoid arthritis treatment agents currently on the market, and, thus, can be effectively used for prevention or treatment of a TNF-α-related disease.
Inventors:
LEE SOO MIN (KR)
KIM JONG-IN (KR)
GU NAM-JIN (KR)
KIM JEONG-HOON (KR)
HAN DAE HEE (KR)
KOO HEE JUNG (KR)
KIM JONG-IN (KR)
GU NAM-JIN (KR)
KIM JEONG-HOON (KR)
HAN DAE HEE (KR)
KOO HEE JUNG (KR)
Application Number:
PCT/KR2021/016045
Publication Date:
May 12, 2022
Filing Date:
November 05, 2021
Export Citation:
Assignee:
SK CHEMICALS CO LTD (KR)
STANDIGM INC (KR)
STANDIGM INC (KR)
International Classes:
A61K31/5415; A23L33/10; A61P19/00; A61P19/02; A61P29/00; A61P37/00
Domestic Patent References:
| WO2006087229A1 | 2006-08-24 |
Foreign References:
| JP2019529441A | 2019-10-17 | |||
| KR20140023396A | 2014-02-26 | |||
| KR20060133464A | 2006-12-26 | |||
| US20080004285A1 | 2008-01-03 |
Attorney, Agent or Firm:
FIRSTLAW P.C. (KR)
Download PDF: